tiprankstipranks
Trending News
More News >
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market

Innate Pharma (IPHA) Stock Forecast & Price Target

Compare
129 Followers
See the Price Targets and Ratings of:

IPHA Analyst Ratings

Currently, no data available
Based on NaN analysts giving stock ratings to
Innate
Pharma
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IPHA Stock 12 Month Forecast

There Are No Analyst Ratings for IPHA In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

IPHA Financial Forecast

IPHA Earnings Forecast

Next quarter’s earnings estimate for IPHA is -$0.14 with a range of -$0.14 to -$0.14. The previous quarter’s EPS was -$0.30. IPHA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.
Next quarter’s earnings estimate for IPHA is -$0.14 with a range of -$0.14 to -$0.14. The previous quarter’s EPS was -$0.30. IPHA beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.

IPHA Sales Forecast

Next quarter’s sales forecast for IPHA is $2.55M with a range of $2.55M to $2.55M. The previous quarter’s sales results were $1.83M. IPHA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.
Next quarter’s sales forecast for IPHA is $2.55M with a range of $2.55M to $2.55M. The previous quarter’s sales results were $1.83M. IPHA beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year IPHA has Performed in-line its overall industry.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IPHA
H.C. Wainwright
H.C. Wainwright
$5
Buy
184.09%
Upside
Upgraded
10/28/25
Innate Pharma upgraded to Buy from Neutral at H.C. WainwrightInnate Pharma upgraded to Buy from Neutral at H.C. Wainwright
Lucid Capital Analyst forecast on IPHA
Lucid Capital
Lucid Capital
$8
Buy
354.55%
Upside
Initiated
10/23/25
Innate Pharma initiated with a Buy at Lucid CapitalInnate Pharma initiated with a Buy at Lucid Capital
Goldman Sachs Analyst forecast on IPHA
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
Hold
Reiterated
10/08/25
Goldman Sachs Keeps Their Hold Rating on Innate Pharma (IPHA)
Leerink Partners Analyst forecast on IPHA
Leerink Partners
Leerink Partners
$10$2
Hold
13.64%
Upside
Downgraded
09/18/25
Innate Pharma's Strategic Shift and Financial Challenges Lead to Hold Rating
BTIG
$8
Buy
354.55%
Upside
Reiterated
09/17/25
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Innate Pharma (NASDAQ: IPHA)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on IPHA
H.C. Wainwright
H.C. Wainwright
$5
Buy
184.09%
Upside
Upgraded
10/28/25
Innate Pharma upgraded to Buy from Neutral at H.C. WainwrightInnate Pharma upgraded to Buy from Neutral at H.C. Wainwright
Lucid Capital Analyst forecast on IPHA
Lucid Capital
Lucid Capital
$8
Buy
354.55%
Upside
Initiated
10/23/25
Innate Pharma initiated with a Buy at Lucid CapitalInnate Pharma initiated with a Buy at Lucid Capital
Goldman Sachs Analyst forecast on IPHA
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
Hold
Reiterated
10/08/25
Goldman Sachs Keeps Their Hold Rating on Innate Pharma (IPHA)
Leerink Partners Analyst forecast on IPHA
Leerink Partners
Leerink Partners
$10$2
Hold
13.64%
Upside
Downgraded
09/18/25
Innate Pharma's Strategic Shift and Financial Challenges Lead to Hold Rating
BTIG
$8
Buy
354.55%
Upside
Reiterated
09/17/25
Analysts Offer Insights on Healthcare Companies: Maze Therapeutics, Inc. (NASDAQ: MAZE) and Innate Pharma (NASDAQ: IPHA)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innate Pharma

3 Months
xxx
Success Rate
5/15 ratings generated profit
33%
Average Return
-0.63%
upgraded a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -0.63% per trade.
1 Year
Swayampakula RamakanthH.C. Wainwright
Success Rate
4/15 ratings generated profit
27%
Average Return
-10.43%
upgraded a buy rating 3 months ago
Copying Swayampakula Ramakanth's trades and holding each position for 1 Year would result in 26.67% of your transactions generating a profit, with an average return of -10.43% per trade.
2 Years
xxx
Success Rate
3/15 ratings generated profit
20%
Average Return
-14.43%
upgraded a xxx
rating 3 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 20.00% of your transactions generating a profit, with an average return of -14.43% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IPHA Analyst Recommendation Trends

Rating
Jun 25
Jul 25
Sep 25
Oct 25
Nov 25
Strong Buy
1
1
2
4
3
Buy
1
0
0
1
2
Hold
2
4
34
71
79
Sell
0
0
0
2
3
Strong Sell
0
0
0
0
0
total
4
5
36
78
87
In the current month, IPHA has received 5 Buy Ratings, 79 Hold Ratings, and 3 Sell Ratings. IPHA average Analyst price target in the past 3 months is .
Each month's total comprises the sum of three months' worth of ratings.

IPHA Stock Forecast FAQ

What is IPHA’s average 12-month price target, according to analysts?
Currently, no data Available
What is IPHA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for IPHA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is IPHA a Buy, Sell or Hold?
      Currently, no data Available
      What is Innate Pharma’s price target?
      Currently, no data Available
      What do analysts say about Innate Pharma?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of IPHA?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.